WO2009043759A3 - Short rna antagonist compounds for the modulation of hif1alpha - Google Patents
Short rna antagonist compounds for the modulation of hif1alpha Download PDFInfo
- Publication number
- WO2009043759A3 WO2009043759A3 PCT/EP2008/062658 EP2008062658W WO2009043759A3 WO 2009043759 A3 WO2009043759 A3 WO 2009043759A3 EP 2008062658 W EP2008062658 W EP 2008062658W WO 2009043759 A3 WO2009043759 A3 WO 2009043759A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hif1alpha
- modulation
- antagonist compounds
- short rna
- rna antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to oligomer compounds (oligomers) of 12, 13 or 14 nucleotides in length, which target Hif1 alpha mRNA in a cell, leading to reduced expression of Hif1 alpha. Reduction of Hif 1 alpha expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08804580A EP2205738A2 (en) | 2007-10-04 | 2008-09-23 | Short rna antagonist compounds for the modulation of hif1alpha |
JP2010527403A JP2010539961A (en) | 2007-10-04 | 2008-09-23 | Short RNA antagonist compounds for modulation of HIF1α |
CA2701895A CA2701895A1 (en) | 2007-10-04 | 2008-09-23 | Short rna antagonist compounds for the modulation of hif1alpha |
US12/753,588 US20100249219A1 (en) | 2007-10-04 | 2010-04-02 | Short rna antagonist compounds for the modulation of hif-1alpha |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97740907P | 2007-10-04 | 2007-10-04 | |
US60/977,409 | 2007-10-04 | ||
PCT/EP2008/053314 WO2008113832A2 (en) | 2007-03-22 | 2008-03-19 | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
EPPCT/EP2008/053314 | 2008-03-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/753,588 Continuation-In-Part US20100249219A1 (en) | 2007-10-04 | 2010-04-02 | Short rna antagonist compounds for the modulation of hif-1alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009043759A2 WO2009043759A2 (en) | 2009-04-09 |
WO2009043759A3 true WO2009043759A3 (en) | 2009-07-09 |
Family
ID=40262052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/062658 WO2009043759A2 (en) | 2007-10-04 | 2008-09-23 | Short rna antagonist compounds for the modulation of hif1alpha |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100249219A1 (en) |
JP (1) | JP2010539961A (en) |
CA (1) | CA2701895A1 (en) |
WO (1) | WO2009043759A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
US10815481B2 (en) | 2014-12-16 | 2020-10-27 | Roche Innovation Center Copenhagen A/S | Chiral library screen |
US10955407B2 (en) | 2015-10-22 | 2021-03-23 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
MA45496A (en) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION |
JP2021502059A (en) * | 2017-10-13 | 2021-01-28 | ロシュ イノベーション センター コペンハーゲン エーエス | A method for identifying improved three-dimensionally defined phosphorothioate oligonucleotide variants of antisense oligonucleotides by using a sub-library of partially three-dimensionally defined oligonucleotides. |
CA3072314A1 (en) | 2017-10-16 | 2019-04-25 | F. Hoffmann-La Roche Ag | Nucleic acid molecule for reduction of papd5 and papd7 mrna for treating hepatitis b infection |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050734A2 (en) * | 2004-11-09 | 2006-05-18 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
WO2007085485A2 (en) * | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
WO2008113832A2 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
ES2649817T3 (en) * | 2002-04-05 | 2018-01-15 | Roche Innovation Center Copenhagen A/S | Oligomeric compounds for modulation of the expression of HIF-1¿Á |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
-
2008
- 2008-09-23 JP JP2010527403A patent/JP2010539961A/en not_active Withdrawn
- 2008-09-23 CA CA2701895A patent/CA2701895A1/en not_active Abandoned
- 2008-09-23 WO PCT/EP2008/062658 patent/WO2009043759A2/en active Application Filing
-
2010
- 2010-04-02 US US12/753,588 patent/US20100249219A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050734A2 (en) * | 2004-11-09 | 2006-05-18 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
WO2007085485A2 (en) * | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
WO2008113832A2 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
Non-Patent Citations (1)
Title |
---|
KURRECK J ET AL: "Design of antisense oligonucleotides stabilized by locked nucleic acids", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 30, no. 9, 1 May 2002 (2002-05-01), pages 1911 - 1918, XP002281375, ISSN: 0305-1048 * |
Also Published As
Publication number | Publication date |
---|---|
CA2701895A1 (en) | 2009-04-09 |
US20100249219A1 (en) | 2010-09-30 |
WO2009043759A2 (en) | 2009-04-09 |
JP2010539961A (en) | 2010-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009068033A3 (en) | Lna antagonists targeting the androgen receptor | |
WO2009071082A9 (en) | Rna antagonist compounds for the modulation of pik3ca expression | |
WO2008132234A3 (en) | Rna antagonist compounds for the modulation of beta-catenin | |
WO2013074974A3 (en) | Modified rnai agents | |
WO2010007522A8 (en) | Rna antagonists targeting gli2 | |
WO2006047842A3 (en) | Modified nucleosides for rna interference | |
WO2010041913A3 (en) | Novel uses of grs proteins or fragments thereof | |
WO2009044899A1 (en) | Nucleic acid capable of regulating the proliferation of cell | |
WO2009043759A3 (en) | Short rna antagonist compounds for the modulation of hif1alpha | |
HK1133680A1 (en) | Nucleic acid enzymes and complexes and methods for their use | |
EP2194129A3 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
EP2666859A3 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
WO2009111643A3 (en) | Microrna markers for recurrence of colorectal cancer | |
WO2009155001A3 (en) | Wnt protein signalling inhibitors | |
WO2008138904A3 (en) | Rna antagonist compounds for the modulation of her3 | |
WO2009151598A8 (en) | Diazacarbazoles and methods of use | |
WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
BR112014028787A2 (en) | Non-Small Cell Lung Cancer Treatment Method | |
TN2014000200A1 (en) | Compounds for the modulation of smn2 splicing | |
WO2010003420A3 (en) | Treatment of psoriasis and related diseases by mirna modulation | |
WO2008051523A3 (en) | Carbazole derivatives useful as medicaments in cancer therapy | |
WO2011021177A3 (en) | Compositions and methods for prognosis and treatment of prostate cancer | |
WO2010072770A3 (en) | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering | |
WO2009111336A3 (en) | Methods of purifying plasmid dna | |
WO2010011700A3 (en) | Treatment of cancers characterized by chromosomal rearrangement of the nut gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08804580 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010527403 Country of ref document: JP Ref document number: 2701895 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008804580 Country of ref document: EP |